The global venous diseases treatment market is projected to register a CAGR of 7.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Global Venous Diseases Treatment Market, By Product Type (Ablation Devices, Venous Stents, Venous Closure Products, Sclerotherapy Injection and Others), Disease Type (Deep Vein Thrombosis (DVT), Chronic Venous Insufficiency (CVI), Pulmonary Embolism, Superficial Thrombophlebitis, Varicose Veins and Others), Treatment Type (Surgeries, Scelrotherapy, Angioplasty Or Stenting, Vein Legation and Stripping, Vena Cava Filter, Ambulatory Phlebectomy, Radiofrequency Ablation Therapy, Laser Treatment and Other Therapies) End User (Hospitals, Clinics, Ambulatory Surgical Centers and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, Russia, Italy, U.K., Spain, Turkey, Netherlands, Belgium, Switzerland, Ireland, Rest of Europe, China, India, Japan, Indonesia, Philippines, Thailand, Australia, Malaysia, South Korea, Singapore, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the venous diseases treatment market are:
Rising incidence of venous diseases
Technological advancement in the treatment of venous diseases
Increase in the geriatric population
Market Players:
The key market players for the global venous diseases treatment market are listed below:
Abbott
Alma Lasers
Angiodynamics
B.Braun Melsungen AG
Baylis Medical Company, Inc
BD
Boston Scientific Corporation
Candela Medical
Carl Zeiss Meditec AG
Cook
Imricor
Koninklijke Philips N.V.
Medtronic
Olympus Corporation
Optimed Medizinische Instrumente GmbH
Plusmedica.de
SCITECH
Smith + Nephew
Sonablate
Stryker
Teleflex Incorporated
Terumo Corporation
Theraclion
Varian Medical Systems, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 52
- 1.1 OBJECTIVES OF THE STUDY 52
- 1.2 MARKET DEFINITION 52
- 1.3 OVERVIEW OF THE GLOBAL VENOUS DISEASES TREATMENT MARKET 52
- 1.4 CURRENCY AND PRICING 54
- 1.5 LIMITATIONS 55
- 1.6 MARKETS COVERED 55
2 MARKET SEGMENTATION 60
- 2.1 MARKETS COVERED 60
- 2.2 GEOGRAPHICAL SCOPE 61
- 2.3 YEARS CONSIDERED FOR THE STUDY 62
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 63
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
- 2.6 MULTIVARIATE MODELLING 67
- 2.7 MARKET END USER COVERAGE GRID 68
- 2.8 INSTRUMENT BASED LIFELINE CURVE 69
- 2.9 DBMR MARKET POSITION GRID 70
- 2.10 VENDOR SHARE ANALYSIS 72
- 2.11 SECONDARY SOURCES 73
- 2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
- 4.1 PESTEL ANALYSIS 80
- 4.2 PORTER'S FIVE FORCES 81
5 GLOBAL VENOUS DISEASES TREATMENT MARKET, INDUSTRY INSIGHTS 82
6 EPIDEMIOLOGY 84
7 REGULATORY FRAMEWORK 85
8 MARKET OVERVIEW 88
- 8.1 DRIVERS 90
- 8.1.1 RISING INCIDENCES OF VENOUS DISEASES 90
- 8.1.2 RAPID CHANGES IN LIFESTYLE LEAD TO OBESITY RESULTING IN VENOUS DISEASES 90
- 8.1.3 INCREASE IN THE GERIATRIC POPULATION 91
- 8.1.4 TECHNOLOGICALLY ADVANCEMENT IN THE TREATMENT OF VENOUS DISEASES 92
- 8.2 RESTRAINTS 93
- 8.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 93
- 8.2.2 INADEQUATE REIMBURSEMENT COVERAGE 93
- 8.3 OPPORTUNITIES 94
- 8.3.1 RISING AWARENESS TOWARDS VENOUS DISORDERS 94
- 8.3.2 NEED FOR PROPER DIAGNOSIS AND TREATMENT OF VENOUS DISEASES 94
- 8.3.3 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 95
- 8.3.4 OCCUPATIONAL LIFESTYLE INCREASES THE NEED FOR VENOUS DISEASE TREATMENT 95
- 8.4 CHALLENGES 96
- 8.4.1 HIGH COST ASSOCIATED WITH VENOUS DISEASE TREATMENT 96
- 8.4.2 SIDE EFFECTS AND RISK ASSOCIATED WITH DIFFERENT TREATMENT MODES 97
9 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY PRODUCT TYPE 98
- 9.1 OVERVIEW 99
- 9.2 SCLEROTHERAPY INJECTION 102
- 9.2.1 SCLEROTHERAPY, BY TYPE 102
- 9.2.1.1 INTRAVENOUS 103
- 9.2.1.2 INTRADERMAL 103
- 9.2.1.3 SUBCUTANEOUS 103
- 9.2.2 SUBCUTANEOUS, BY APPLICATION 103
- 9.2.2.1 MALFORMED LYMPHED VESSELS 103
- 9.2.2.2 HEMORRHOIDS 103
- 9.2.2.3 HYDROCELES 103
- 9.2.2.4 OTHERS 103
- 9.3 ABLATION DEVICES 103
- 9.3.1 THERMAL ABLATION 104
- 9.3.1.1 RADIOFREQUENCY 105
- 9.3.1.1.1 CATHETER MANIPULATION SYSTEMS 105
- 9.3.1.1.2 TEMPERATURE CONTROLLED 105
- 9.3.1.1.3 FLUID COOLED 106
- 9.3.1.2 LIGHT 106
- 9.3.1.2.1 EXCIMER LASERS 106
- 9.3.1.2.2 COLD LASERS 106
- 9.3.1.3 ULTRASOUND 106
- 9.3.1.3.1 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) 107
- 9.3.1.3.2 SHOCK WAVE LITHOTRIPSY 107
- 9.3.1.3.3 MAGNETIC RESONANCE IMAGING GUIDED FOCUSED ULTRASOUND (MRI-FUS) 107
- 9.3.1.3.4 ULTRASONIC SURGICAL SYSTEMS 107
- 9.3.1.4 RADIATION 107
- 9.3.1.4.1 STEREOTACTIC BODY RADIATION THERAPY 108
- 9.3.1.4.2 INTENSITY-MODULATED RADIATION THERAPY 108
- 9.3.1.4.3 STEREOTACTIC RADIOTHERAPY & RADIOSURGERY 108
- 9.3.1.4.4 IMAGE GUIDED RADIATION THERAPY 108
- 9.3.1.4.5 INTRAVASCULAR BRACHYTHERAPY 108
- 9.3.1.4.6 PROTON BEAM THERAPY 108
- 9.3.1.5 ELECTRICAL 108
- 9.3.1.5.1 ELECTRICAL ABLATORS 109
- 9.3.1.5.2 ELECTRONIC BRACHYTHERAPY 109
- 9.3.1.6 MICROWAVE 109
- 9.3.1.7 HYDROTHERMAL 109
- 9.3.2 NON-THERMAL ABLATION 109
- 9.3.2.1 CRYOABLATION 109
- 9.3.2.1.1 EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 110
- 9.3.2.1.2 CRYOGEN SPRAY PROBE 110
- 9.3.2.1.3 TISSUE CONTACT PROBE 110
- 9.3.2.2 HYDROMECHANICAL ABLATION 110
- 9.4 VENOUS CLOSURE PRODUCTS 110
- 9.4.1 VENOUS CLOSURE PRODUCTS, BY PROCEDURE 111
- 9.4.1.1 INTERVENTIONAL CARDIOLOGY 111
- 9.4.1.2 INTERVENTIONAL RADIOLOGY 111
- 9.4.2 VENOUS CLOSURE PRODUCTS, BY TECHNOLOGY 111
- 9.4.2.1 FEMORAL ACCESS TECHNIQUE 112
- 9.4.2.2 RADIAL ACCESS TECHNIQUE 112
- 9.5 VENOUS STENTS 112
- 9.5.1 VENOUS STENTS, BY TECHNOLOGY 113
- 9.5.1.1 WALLSTENT TECHNOLOGY 113
- 9.5.1.2 ILIAC VEIN STENT TECHNOLOGY 113
- 9.5.2 VENOUS STENTS, BY APPLICATION 113
- 9.5.2.1 LEG 114
- 9.5.2.2 CHEST 114
- 9.5.2.3 ABDOMEN 114
- 9.5.2.4 OTHERS 114
- 9.6 MEDICATION 114
- 9.7 OTHERS 115
10 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY DISEASE TYPE 116
- 10.1 OVERVIEW 117
- 10.2 VARICOSE VEINS 120
- 10.3 DEEP VEIN THROMBOSIS (DVT) 120
- 10.4 PULMONARY EMBOLISM 121
- 10.5 CHRONIC VENOUS INSUFFICIENCY (CVI) 122
- 10.6 SUPERFICIAL THROMBOPHLEBITIS 122
- 10.7 OTHERS 123
11 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY TREATMENT TYPE 125
- 11.1 OVERVIEW 126
- 11.2 SCLEROTHERAPY 129
- 11.3 RADIOFREQUENCY ABLATION THERAPY 129
- 11.4 LASER TREATMENT 130
- 11.5 AMBULATORY PHLEBECTOMY 131
- 11.6 VEIN LIGATION AND STRIPPING 131
- 11.7 ANGIOPLASTY OR STENTING 132
- 11.8 SURGERIES 133
- 11.9 COMPRESSION THERAPY 133
- 11.10 VEINACTIVE MEDICATION 134
- 11.11 VENA CAVA FILTER 135
- 11.12 OTHER THERAPIES 136
12 GLOBAL VENOUS TREATMENT DISEASES MARKET, BY END USER 137
- 12.1 OVERVIEW 138
- 12.2 HOSPITALS 141
- 12.3 CLINICS 141
- 12.4 AMBULATORY SURGICAL CENTERS 142
- 12.5 OTHERS 143
13 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 144
- 13.1 OVERVIEW 145
- 13.2 DIRECT TENDER 148
- 13.3 RETAIL SALES 148
- 13.4 OTHERS 149
14 GLOBAL VENOUS DISEASES TREATMENT MARKET, BY REGION 150
- 14.1 OVERVIEW 151
- 14.2 NORTH AMERICA 156
- 14.2.1 U.S. 166
- 14.2.2 CANADA 172
- 14.2.3 MEXICO 178
- 14.3 EUROPE 184
- 14.3.1 GERMANY 195
- 14.3.2 U.K. 201
- 14.3.3 FRANCE 207
- 14.3.4 ITALY 213
- 14.3.5 RUSSIA 219
- 14.3.6 SPAIN 225
- 14.3.7 TURKEY 231
- 14.3.8 NETHERLANDS 237
- 14.3.9 BELGIUM 243
- 14.3.10 SWITZERLAND 249
- 14.3.11 IRELAND 255
- 14.3.12 REST OF EUROPE 261
- 14.4 ASIA-PACIFIC 262
- 14.4.1 CHINA 272
- 14.4.2 JAPAN 278
- 14.4.3 INDIA 284
- 14.4.4 AUSTRALIA 290
- 14.4.5 INDONESIA 296
- 14.4.6 SINGAPORE 302
- 14.4.7 MALAYSIA 308
- 14.4.8 PHILIPPINES 314
- 14.4.9 SOUTH KOREA 320
- 14.4.10 THAILAND 326
- 14.4.11 REST OF ASIA-PACIFIC 332
- 14.5 SOUTH AMERICA 333
- 14.5.1 BRAZIL 344
- 14.5.2 ARGENTINA 350
- 14.5.3 REST OF SOUTH AMERICA 356
- 14.6 MIDDLE EAST & AFRICA 357
- 14.6.1 SOUTH AFRICA 368
- 14.6.2 SAUDI ARABIA 374
- 14.6.3 U.A.E. 380
- 14.6.4 EGYPT 386
- 14.6.5 ISRAEL 392
- 14.6.6 REST OF MIDDLE EAST AND AFRICA 398
15 GLOBAL VENOUS DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 399
- 15.1 COMPANY SHARE ANALYSIS: GLOBAL 399
- 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 400
- 15.3 COMPANY SHARE ANALYSIS: EUROPE 401
- 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 402
16 SWOT ANALYSIS 403
17 COMPANY PROFILE 404
- 17.1 MEDTRONIC 404
- 17.1.1 COMPANY SNAPSHOT 404
- 17.1.2 REVENUE ANALYSIS 404
- 17.1.3 COMPANY SHARE ANALYSIS 405
- 17.1.4 PRODUCT PORTFOLIO 405
- 17.1.5 RECENT DEVELOPMENTS 405
- 17.2 BOSTON SCIENTIFIC CORPORATION 406
- 17.2.1 COMPANY SNAPSHOT 406
- 17.2.2 REVENUE ANALYSIS 406
- 17.2.3 COMPANY SHARE ANALYSIS 407
- 17.2.4 PRODUCT PORTFOLIO 407
- 17.2.5 RECENT DEVELOPMENTS 408
- 17.3 VARIAN MEDICAL SYSTEMS, INC. 409
- 17.3.1 COMPANY SNAPSHOT 409
- 17.3.2 COMPANY SHARE ANALYSIS 409
- 17.3.3 PRODUCT PORTFOLIO 410
- 17.3.4 RECENT DEVELOPMENT 410
- 17.4 STRYKER 411
- 17.4.1 COMPANY SNAPSHOT 411
- 17.4.2 REVENUE ANALYSIS 411
- 17.4.3 COMPANY SHARE ANALYSIS 412
- 17.4.4 PRODUCT PORTFOLIO 412
- 17.4.5 RECENT DEVELOPMENT 412
- 17.5 KONINKLIJKE PHILIPS N.V. 413
- 17.5.1 COMPANY SNAPSHOT 413
- 17.5.2 REVENUE ANALYSIS 413
- 17.5.3 COMPANY SHARE ANALYSIS 414
- 17.5.4 PRODUCT PORTFOLIO 414
- 17.5.5 RECENT DEVELOPMENT 414
- 17.6 ABBOTT 415
- 17.6.1 COMPANY SNAPSHOT 415
- 17.6.2 REVENUE ANALYSIS 415
- 17.6.3 PRODUCT PORTFOLIO 416
- 17.6.4 RECENT DEVELOPMENT 416
- 17.7 ALMA LASERS 417
- 17.7.1 COMPANY SNAPSHOT 417
- 17.7.2 PRODUCT PORTFOLIO 417
- 17.7.3 RECENT DEVELOPMENT 417
- 17.8 ANGIODYNAMICS 418
- 17.8.1 COMPANY SNAPSHOT 418
- 17.8.2 REVENUE ANALYSIS 418
- 17.8.3 PRODUCT PORTFOLIO 419
- 17.8.4 RECENT DEVELOPMENT 419
- 17.9 B.BRAUN MELSUNGEN AG 420
- 17.9.1 COMPANY SNAPSHOT 420
- 17.9.2 REVENUE ANALYSIS 420
- 17.9.3 PRODUCT PORTFOLIO 421
- 17.9.4 RECENT DEVELOPMENTS 421
- 17.10 BAYLIS MEDICAL COMPANY, INC 422
- 17.10.1 COMPANY SNAPSHOT 422
- 17.10.2 PRODUCT PORTFOLIO 422
- 17.10.3 RECENT DEVELOPMENT 422
- 17.11 BD 423
- 17.11.1 COMPANY SNAPSHOT 423
- 17.11.2 REVENUE ANALYSIS 423
- 17.11.3 PRODUCT PORTFOLIO 424
- 17.11.4 RECENT DEVELOPMENT 424
- 17.12 CANDELA MEDICAL 425
- 17.12.1 COMPANY SNAPSHOT 425
- 17.12.2 PRODUCT PORTFOLIO 425
- 17.12.3 RECENT DEVELOPMENT 425